1. MAPK/ERK Pathway Autophagy Apoptosis
  2. p38 MAPK Autophagy Apoptosis
  3. Hesperetin

Hesperetin  (Synonyms: 橙皮素)

目录号: HY-N0168 纯度: 98.87%
COA 产品使用指南

Hesperetin 是一种天然黄烷酮类物质,为有效的,广谱的人 UGT 抑制剂。Hesperetin 可调节凋亡途径。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Hesperetin Chemical Structure

Hesperetin Chemical Structure

CAS No. : 520-33-2

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥550
In-stock
50 mg ¥500
In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Hesperetin:

    Hesperetin purchased from MCE. Usage Cited in: Nutr Cancer. 2020;72(3):538-545.  [Abstract]

    Hesperetin induced G2/M arrest in GBM cell. Cells are treated with vehicle or various doses of hesperetin for 24 h. Whole cell lysates are immunoblotted with indicated antibodies. The protein levels of p21, CDK1, and cyclin B1 are measured by western blotting.

    Hesperetin purchased from MCE. Usage Cited in: Nutr Cancer. 2020;72(3):538-545.  [Abstract]

    p38 MAPK activation is involved in Hesperetin-induced apoptosis. The phosphorylation of p38 MAPK, JNK, and ERK in U-21 cells treated with hesperetin is analyzed by western blotting.

    Hesperetin purchased from MCE. Usage Cited in: Nutr Cancer. 2020;72(3):538-545.  [Abstract]

    U-251 cells are cultured with indicated concentration of Hesperetin for 24 h. Then the cells are stained with DAPI and observed under a fluorescence microscope.

    Hesperetin purchased from MCE. Usage Cited in: Nutr Cancer. 2020;72(3):538-545.  [Abstract]

    The expression of Bax and Bcl-2 was examined by western blotting. GAPDH was served as a loading control.

    查看 p38 MAPK 亚型特异性产品:

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Hesperetin is a natural flavanone, and acts as a potent and broad-spectrum inhibitor against human UGT activity. Hesperetin regulates apoptosis.

    体外研究
    (In Vitro)

    Hesperetin 在自纳米乳化给药系统中具有抗氧化潜力[1]。Hesperetin 和 NGR 显示出对人类 μgT 的广谱抑制作用。此外,Hesperetin 对 μgT1A1、1A3 和 1A9 具有强抑制作用 (IC50 和 Ki 值均低于 10 μM),中度抑制 μgT1A4、ugT1A7、ugT1A8 (IC 50 值 29.68-63.87 μM)[2]。Hesperetin 与不同类型的蛋白质相互作用,包括氢键、pi-pi 效应、pi-阳离子键合和 pi-sigma 相互作用,具有不同的结合能。Hesperetin 具有类似药物的特性,这表明它具有作为 CHIKV 感染处理选择的潜力[3]。Hesperetin 以剂量依赖性方式降低培养的原代大鼠肝细胞中 GCDCA 诱导的 caspase-3 活性。Hesperetin 还剂量依赖性地降低肝细胞中 CM 诱导的 Nos2 (iNOS) 表达。有趣的是,与单独使用细胞因子混合物相比,Hesperetin 诱导的抗氧化基因血红素加氧酶 1 (HO-1) 的表达增加了约四倍[5]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    预先给予 Hesperetin (40 mg/kg,口服) 可显著减轻 Cd 诱导的氧化应激和线粒体功能障碍,恢复抗氧化和膜结合酶活性并减少大鼠脑细胞凋亡[4]。Hesperetin (200 mg/kg) 减弱 Con A 诱导的小鼠肝细胞凋亡和肝 Nos2 (iNOS) 表达。Hesperetin 联合处理还减少了凋亡小体、水肿变性、核碎片、自溶和出血的发生。在小鼠模型中,Hesperetin 显著降低了 D-GalN/LPS 诱导的暴发性肝炎小鼠肝组织中浸润的白细胞数量[5]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    302.28

    Formula

    C16H14O6

    CAS 号
    性状

    固体

    颜色

    Light yellow to yellow

    中文名称

    橙皮素

    结构分类
    初始来源
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    In Vitro: 

    DMSO 中的溶解度 : 125 mg/mL (413.52 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 3.3082 mL 16.5410 mL 33.0819 mL
    5 mM 0.6616 mL 3.3082 mL 6.6164 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    In Vivo:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (8.27 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.27 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      20% SBE-β-CD in Saline 的配制(4°C,储存一周):2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

    以下溶解方案,请直接配置工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂: 0.5% CMC/saline water

      Solubility: 20 mg/mL (66.16 mM); 悬浊液; 超声助溶

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料
    参考文献
    Kinase Assay
    [4]

    First, 0.5 mL tissue homogenate is diluted with 1 mL water. Then, to this mixture, 2.5 mL ethanol and 1.5 mL chloroform (all reagents chilled) are added and shaken for 1 min at 4°C, then centrifuged. The enzyme activity in the supernatant is determined. The assay mixture contained 1.2 mL sodium pyrophosphate buffer (0.025 M, pH 8.3), 0.1 mL 186 mM phenazine methosulfate (PMS), 0.3 mL 30 mM Nitroblue tetrazolium (NBT), and 0.2 mL of nicotinamide adenine dinucleotide (NADH), and appropriately diluted enzyme preparation and water in a total volume of 3 mL. Reaction is initiated by the addition of NADH. After incubation at 30°C for 90 min, the reaction is stopped by the addition of 1 mL glacial acetic acid. The reaction mixture is stirred vigorously and shaken with 4 mL n-butanol. The intensity of the chromogen in the butanol layer is measured at 560 nm against a butanol blank. A system without enzyme served as control. One unit of enzyme activity is defined as 50% inhibition of NBT reduction in 1 min under the assay conditions.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [4]

    After 7 days of adjusting, the animals are randomly divided into 10 experimental groups. Control group (n=8): These animals are treated with the equivalent volume of PBS as used for the administration of Con A and D-GalN/LPS. Control hesperetin group (n=8): The mice are treated with hesperetin 400 mg/kg p.o. in 0.5% sodium carboxymethylcellulose (CMC-Na) solution for 10 days. Con A group (n=15): The animals are treated with the same volume of CMC-Na as used for administration of hesperetin for 10 days and are challenged with Con A (i.v.15 mg/kg). Con A + hesperetin groups: The animals receive various doses of hesperetin (100, 200, 400 mg/kg) p.o. for 10 days before Con A injection (each group n=15). D-GalN/LPS group (n=15): The animals are given CMC-Na for 10 days and injected i.p. with D-GalN (700 mg/kg)/LPS (5 μg/kg). D-GalN/LPS + hesperetin groups: Three doses of hesperetin (100, 200, 400 mg/kg) are given to mice once daily for 10 days. D-GalN (700 mg/kg)/LPS (5 μg/kg) are injected i.p. (each group n=15).

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.3082 mL 16.5410 mL 33.0819 mL 82.7048 mL
    5 mM 0.6616 mL 3.3082 mL 6.6164 mL 16.5410 mL
    10 mM 0.3308 mL 1.6541 mL 3.3082 mL 8.2705 mL
    15 mM 0.2205 mL 1.1027 mL 2.2055 mL 5.5137 mL
    20 mM 0.1654 mL 0.8270 mL 1.6541 mL 4.1352 mL
    25 mM 0.1323 mL 0.6616 mL 1.3233 mL 3.3082 mL
    30 mM 0.1103 mL 0.5514 mL 1.1027 mL 2.7568 mL
    40 mM 0.0827 mL 0.4135 mL 0.8270 mL 2.0676 mL
    50 mM 0.0662 mL 0.3308 mL 0.6616 mL 1.6541 mL
    60 mM 0.0551 mL 0.2757 mL 0.5514 mL 1.3784 mL
    80 mM 0.0414 mL 0.2068 mL 0.4135 mL 1.0338 mL
    100 mM 0.0331 mL 0.1654 mL 0.3308 mL 0.8270 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Hesperetin
    目录号:
    HY-N0168
    需求量: